ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO317

Incremental Peritoneal Dialysis in Incident ESKD Patients

Session Information

Category: Dialysis

  • 703 Dialysis: Peritoneal Dialysis

Authors

  • Yan, Hao, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China
  • Bargman, Joanne M., Toronto General Hospital, Toronto, Ontario, Canada
Background

Incremental peritoneal dialysis (Incre-PD) has been an underused strategy in treating end stage kidney disease (ESKD). This retrospective study analyzed the characteristics and outcomes of ESKD patients undergoing Incre-PD in a large academic center.

Methods

ESKD patients initiating PD with a contact PD volume ≤6 L/day between 2013 and 2017 inclusive were followed up until death, PD cessation, or the end of 2018.

Results

175 Incre-PD patients were identified, accounting for 85% of the incident patients of that period,and were followed up for 352.6 patient-years. Compared to those with initial PD dose >6 L/day, there were more Asians (24.0% vs. 6.7%, p=0.033) but fewer of African descent (13.7% vs. 36.7%, p=0.002) among the Incre-PD patients. The two cohorts were comparable in comorbidity status except for peripheral vascular disease, which was more common in Incre-PD patients (14.3% vs. 0.0%, p=0.030). The baseline urine volume (1.5±0.7 L/day vs. 1.0±0.9 L/day, p=0.001) and residual kidney function (RKF, 8.3±3.4 mL/min/1.73m2 vs. 5.5±3.2 ml/min/1.73m2, p<0.001) were greater in Incre-PD patients, and they were less likely to have undergone hemodialysis (HD) prior to PD (19.4% vs. 50.0%, p<0.001). The baseline daily contact PD volume was 4.5 (IQR 4.3-6) L, and it was 5.4 (4.5-6.0) L, 6.0 (4.5-7.0) L, 6.0 (4.8-8.0) L, 7.0 (5.7-9.8) L, and 8.0 (6.0-9.8) L at 1 to 5 years on PD, respectively. Fifty-seven (32.6%) patients increased PD dose to >6 L/day at a median time of 10.3 (6.2, 15.7) months. The unadjusted 1 to 5-year patient survival rate was 90%, 80%, 65%, 63%, and 49%, respectively, and the corresponding PD technique survival rate was 95%, 89%, 89%, 82%, and 77%. The average peritonitis rate and hospitalization rate was 0.12 and 0.65 episodes per patient-year, respectively. The length of hospitalization was 5.9 days per patient-year. Greater initial daily contact PD volume (HR=1.608, 95% CI 1.089-2.375) was associated with death after adjusting for age, Charlson comorbidity index, HD prior to PD, assisted PD and baseline RKF, likely as a result of residual confounding. It was not a factor related to technique failure. Male sex, greater body mass index and lower serum albumin at PD initiation were risk factors for increasing PD dose to >6 L/day within 1 year.

Conclusion

In the largest reported series to date, Incre-PD is a successful and patient-oriented strategy to treat ESKD patients.